Search results for Daratumumab ELISA Kit
Daratumumab ELISA Kit, ProteoGenix, KPTX217
Description of Daratumumab ELISA Kit Introduction Daratumumab is a monoclonal antibody that has shown promising results in the treatment of multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. This antibody specifically targets CD38, a protein that is highly expressed on the surface of myeloma cells. To facilitate the monitoring of daratumumab levels in patients, a sensitive and specific enzyme-linked immunosorbent assay (ELISA) kit has been developed. Structure of Daratumumab ELISA Kit The Daratumumab ELISA kit is composed of several components that work together to detect and quantify daratumumab levels in biological samples. The kit contains pre-coated microtiter plates, which are coated with a highly specific capture antibody against daratumumab. This antibody is immobilized on the surface of the plate and serves as the solid phase for the ELISA. The kit also includes a detection antibody, which is labeled with an enzyme such as horseradish peroxidase (HRP). This detection antibody is specific for a different epitope on daratumumab and is used to detect the bound daratumumab on the plate. The HRP enzyme catalyzes a colorimetric reaction, which can be measured using a spectrophotometer. Principle of the Assay The Daratumumab ELISA kit utilizes the principle of sandwich ELISA, where the capture antibody and the detection antibody bind to different epitopes on the target molecule, in this case, daratumumab. The sample, which may contain daratumumab, is added to the pre-coated microtiter plate and allowed to incubate. If daratumumab is present in the sample, it will bind to the capture antibody on the plate. After washing away any unbound material, the labeled detection antibody is added to the plate and allowed to bind to the captured daratumumab. Any excess detection antibody is washed away, and a substrate solution is added to the plate. The HRP enzyme in the detection antibody catalyzes a colorimetric reaction, which produces a color change that is directly proportional to the amount of daratumumab present in the sample. Application of Daratumumab ELISA Kit The Daratumumab ELISA kit has several applications in the field of cancer research and treatment. One of the main applications is in the monitoring of daratumumab levels in patients undergoing treatment for multiple myeloma. By measuring the levels of daratumumab in the blood, doctors can assess the effectiveness of the treatment and make any necessary adjustments. The kit can also be used to measure the pharmacokinetics of daratumumab, including its absorption, distribution, metabolism, and excretion in the body. This information is crucial for optimizing the dosing and administration of daratumumab in patients. Moreover, the Daratumumab ELISA kit can be used in preclinical studies to evaluate the pharmacological properties of daratumumab, such as its half-life, binding affinity, and specificity. This information is essential for the development and optimization of new daratumumab-based therapies. Conclusion In summary, the Daratumumab ELISA kit provides a sensitive and specific method for the detection and quantification of daratumumab levels in biological samples. Its use in monitoring daratumumab levels in patients and assessing its pharmacokinetics has significant implications for the treatment of multiple myeloma. With the continued development and optimization of daratumumab-based therapies, the Daratumumab ELISA kit will play a crucial role in advancing cancer research and treatment.
Host
Reactivity
Applications
Conjugation
Daratumumab ELISA Kit, Abbexa, abx395106
Daratumumab ELISA Kit is a quantitative ELISA kit for detection of Daratumumab.Daratumumab is human IgG1 monoclonal antibody to CD38, which is a transmembrane glycoprotein that is frequently overexpressed on cancer cells including multiple myeloma cells. The monoclonal antibody binds to the CD38 molecule and triggers cell apoptosis, probably as a result of antibody mediated cytotoxicity. Daratumumab has been evaluated in heavily pretreated patients with refractory multiple myeloma and shown overall response rates of higher than expected. Daratumumab was given accelerated approval in the United States in 2015 for use in multiple myeloma. Current indications are as therapy of patients with refractory multiple myeloma in combination with lenalidomide (or bortezomib) and dexamethasone or as monotherapy in patients who have failed at least three previous regimens. Daratumumab is available as a solution for intravenous infusion in single use vials of 100 mg in 5 mL or 400 mg in 20 mL (20 mg/mL). The recommended dose is 16 mg/kg intravenously every week for 8 to 9 weeks, and then every 2, 3 or 4 weeks based upon indications and other agents being used. Premedication with methylprednisolone is recommended. Side effects are common and can include infusion reactions, bone marrow suppression, fatigue, nausea and vomiting, diarrhea, muscle spasms, back pain, fever, cough, dyspnea, peripheral edema, peripheral neuropathy and upper respiratory infection. Rare, but potentially serious side effects include severe infusion reactions, neutropenia, thrombocytopenia and interference with cross matching and red blood cell antibody screening.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.